Eptifibatide
FDA-approved platelet surface receptors called GPIIb/IIIa (needed for clumping) inhibitor (Integrilin).
What it's for
FDA-approved platelet surface receptors called GPIIb/IIIa (needed for clumping) inhibitor (Integrilin).
What it's for
Eptifibatide is a ring-shaped 7–amino-acid peptide that blocks platelet glycoprotein IIb/IIIa receptors (lock-and-key landing spots on cells). Used in acute coronary syndromes and during PCI (a heart artery procedure) to reduce ischemic complications as labeled.
What it does for the body
Used in acute coronary syndromes and during PCI (a heart artery procedure) to reduce ischemic complications as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It targets platelet surface receptors called platelet surface receptors called GPIIb/IIIa (needed for clumping), which platelets need to stick together. Blocking that link helps prevent fibrinogen from chaining platelets into a clot during certain heart procedures or acute coronary syndromes — as labeled.
Research context
Bottom line for readers: Eptifibatide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Eptifibatide — FDA.gov search
- ClinicalTrials.gov search: Eptifibatide — U.S. clinical trials registry
- Drugs@FDA search: Eptifibatide — FDA drug database (if approved)
- PubMed search: Eptifibatide — NCBI PubMed
- PubMed Central search: Eptifibatide — NCBI PMC